AU2003248893A8 - Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias - Google Patents
Compositions and methods for the treatment of parkinson's disease and tardive dyskinesiasInfo
- Publication number
- AU2003248893A8 AU2003248893A8 AU2003248893A AU2003248893A AU2003248893A8 AU 2003248893 A8 AU2003248893 A8 AU 2003248893A8 AU 2003248893 A AU2003248893 A AU 2003248893A AU 2003248893 A AU2003248893 A AU 2003248893A AU 2003248893 A8 AU2003248893 A8 AU 2003248893A8
- Authority
- AU
- Australia
- Prior art keywords
- parkinson
- disease
- compositions
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/192,414 US20020198231A1 (en) | 1999-07-13 | 2002-07-09 | Compositions and methods for the treatment of Parkinson's disease |
US10/192,414 | 2002-07-09 | ||
US47974803P | 2003-06-19 | 2003-06-19 | |
US60/479,748 | 2003-06-19 | ||
PCT/US2003/021463 WO2004004660A2 (en) | 2002-07-09 | 2003-07-09 | Compositions and methods for the treatment of parkinson’s disease and tardive dyskinesias |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003248893A1 AU2003248893A1 (en) | 2004-01-23 |
AU2003248893A8 true AU2003248893A8 (en) | 2004-01-23 |
Family
ID=30117814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003248893A Abandoned AU2003248893A1 (en) | 2002-07-09 | 2003-07-09 | Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1581167A4 (en) |
JP (1) | JP2006514917A (en) |
AU (1) | AU2003248893A1 (en) |
CA (1) | CA2531810A1 (en) |
WO (1) | WO2004004660A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007067714A2 (en) | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
CA2642672A1 (en) * | 2006-02-16 | 2007-08-30 | The Mclean Hospital Corporation | Methods and compositions for the treatment of parkinson's disease |
WO2010141712A2 (en) * | 2009-06-03 | 2010-12-09 | Marquette University | Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
EP2509953B1 (en) * | 2009-12-11 | 2016-03-30 | Genecode AS | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
CN113354581B (en) * | 2020-03-06 | 2023-06-20 | 华南理工大学 | Preparation method and application of chiral chloroquine and phosphate thereof |
CN113527201A (en) * | 2020-04-14 | 2021-10-22 | 瀚海新拓(杭州)生物医药有限公司 | Optically active chloroquine and hydroxychloroquine and analogs thereof, preparation method, composition and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5430039A (en) * | 1990-09-28 | 1995-07-04 | Cephalon, Inc. | Treatment of neurological disorders |
US5496836A (en) * | 1994-05-05 | 1996-03-05 | Mount Sinai School Of Medicine Of The City University Of New York | Use of famotidine and related compounds in the treatment of movement disorders |
DE4428199A1 (en) * | 1994-08-09 | 1996-02-15 | Univ Ludwigs Albert | Use of flunitrazepam and/or chloroquine |
CA2416233A1 (en) * | 1999-07-13 | 2001-01-18 | Alpha Research Group, Llc | Compositions and methods for the treatment of parkinson's disease |
-
2003
- 2003-07-09 WO PCT/US2003/021463 patent/WO2004004660A2/en active Search and Examination
- 2003-07-09 JP JP2004520071A patent/JP2006514917A/en active Pending
- 2003-07-09 CA CA002531810A patent/CA2531810A1/en not_active Abandoned
- 2003-07-09 AU AU2003248893A patent/AU2003248893A1/en not_active Abandoned
- 2003-07-09 EP EP03763398A patent/EP1581167A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2531810A1 (en) | 2004-01-15 |
AU2003248893A1 (en) | 2004-01-23 |
JP2006514917A (en) | 2006-05-18 |
EP1581167A4 (en) | 2008-10-29 |
WO2004004660A3 (en) | 2005-11-03 |
EP1581167A2 (en) | 2005-10-05 |
WO2004004660A2 (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI340640B (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
AU2003223579A8 (en) | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease | |
WO2004030615A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
WO2004016225A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1571968A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
WO2004045516A9 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1571968A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1575480A4 (en) | Compositions and methods for the treatment of immune related diseases | |
EP1578367A4 (en) | Compositions and methods for the treatment of immune related diseases | |
EP1572116A4 (en) | Compositions and methods for the treatment of immune related diseases | |
EP1576137A4 (en) | Compositions and methods for the treatment of immune related diseases | |
IL175529A0 (en) | Methods and compositions for the treatment of metabolic disorders | |
WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
EP1572091A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1572091A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
WO2004060270A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1553912A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
WO2003057160A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1560593A4 (en) | Novel composition and methods for the treatment of immune related diseases | |
ZA200605555B (en) | Compositions and methods of administering tubulin binding agents for the treatment of ocular disease | |
AU2003231252A1 (en) | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease | |
EP1680145A4 (en) | Methods and compositions for the treatment of neurological disease | |
PL371281A1 (en) | Methods and compositions for the treatment of eye diseases | |
AU2003254146A1 (en) | Methods for the treatment of parkinson's disease | |
AU2003248893A8 (en) | Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |